Data / Drug companies / WG Critical Care, LLC
WG Critical Care, LLC: 97 products in the FDA NDC directory, labeler code 44567
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
WG Critical Care, LLC (labeler code 44567) lists 97 products in the FDA National Drug Code Directory, covering 28 finished drugs by generic name. By type: 97 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 10, 2025.
The request: Watch WG Critical Care, LLC (FDA labeler code 44567): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 44567
- Products in commercial distribution
- 97
- Packages
- 98
- Finished drugs by generic name
- 28
- Prescription products
- 97
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 2
- Flagged as original packager
- 45 of 45 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- November 25, 2005
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 65 | 67% |
| New drug applications (NDA) | 32 | 33% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 97 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Magnesium sulfate | 8 | 40 |
| Ampicillin | 6 | 10 |
| Ceftriaxone | 6 | 7 |
| Calcium gluconate | 6 | 14 |
| Cefazolin | 6 | 11 |
| Levetiracetam | 5 | 87 |
| Meropenem | 5 | 17 |
| Cefoxitin | 5 | 4 |
| Dexmedetomidine | 4 | 11 |
| Norepinephrine bitartrate | 4 | 25 |
| Ampicillin and sulbactam | 4 | 4 |
| Cisplatin | 4 | 11 |
| Cefepime | 4 | 6 |
| Nafcillin | 3 | 5 |
| Levofloxacin | 3 | 42 |
| Penicillin g potassium | 3 | 8 |
| Piperacillin sodium,tazobactam sodium | 3 | 2 |
| Ceftazidime | 3 | 3 |
| Midazolam | 2 | 6 |
| Nicardipine hydrochloride | 2 | 27 |
| Esmolol hydrochloride in sodium chloride | 2 | 4 |
| Diltiazem hydrochloride | 2 | 55 |
| Esmolol hydrochloride | 2 | 12 |
| Acetaminophen | 1 | 214 |
| Metronidazole | 1 | 68 |
| Imipenem and cilastatin | 1 | 1 |
| Ertapenem | 1 | 5 |
| Piperacillin and tazobactam | 1 | 13 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, for solution | 50 | 51.5% |
| Injection, solution | 24 | 24.7% |
| Injection | 19 | 19.6% |
| Injection, solution, concentrate | 2 | 2.1% |
| Injection, powder, lyophilized, for solution | 2 | 2.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Nicardipine Hydrochloride in Sodium Chloride | 44567-851 | Injection, solution | Generic drugs (ANDA) | July 10, 2025 |
| Nicardipine Hydrochloride in Sodium Chloride | 44567-850 | Injection, solution | Generic drugs (ANDA) | July 10, 2025 |
| DILTIAZEM HYDROCHLORIDE in SODIUM CHLORIDE | 44567-663 | Injection, solution | New drug applications (NDA) | March 21, 2025 |
| DILTIAZEM HYDROCHLORIDE in SODIUM CHLORIDE | 44567-662 | Injection, solution | New drug applications (NDA) | March 21, 2025 |
| Metronidazole | 44567-750 | Injection, solution | Generic drugs (ANDA) | January 31, 2025 |
| Cefazolin | 44567-845 | Injection, powder, for solution | New drug applications (NDA) | May 10, 2024 |
| Meropenem | 44567-402 | Injection, powder, for solution | New drug applications (NDA) | September 8, 2023 |
| Cefazolin | 44567-840 | Injection, powder, for solution | New drug applications (NDA) | May 18, 2023 |
| Acetaminophen | 44567-340 | Injection, solution | Generic drugs (ANDA) | May 3, 2023 |
| Esmolol Hydrochloride | 44567-451 | Injection | Generic drugs (ANDA) | December 7, 2022 |
| Esmolol Hydrochloride | 44567-450 | Injection | Generic drugs (ANDA) | December 7, 2022 |
| Norepinephrine bitartrate in sodium chloride | 44567-643 | Injection, solution | New drug applications (NDA) | September 15, 2022 |
| Norepinephrine bitartrate in sodium chloride | 44567-642 | Injection, solution | New drug applications (NDA) | September 15, 2022 |
| Norepinephrine bitartrate in sodium chloride | 44567-641 | Injection, solution | New drug applications (NDA) | September 15, 2022 |
| Norepinephrine bitartrate in sodium chloride | 44567-640 | Injection, solution | New drug applications (NDA) | September 15, 2022 |
| Ampicillin and Sulbactam | 44567-150 | Injection, powder, for solution | Generic drugs (ANDA) | November 30, 2021 |
| Calcium Gluconate in Sodium Chloride | 44567-622 | Injection, solution | New drug applications (NDA) | July 13, 2021 |
| Meropenem | 44567-146 | Injection, powder, for solution | Generic drugs (ANDA) | June 30, 2021 |
| Meropenem | 44567-145 | Injection, powder, for solution | Generic drugs (ANDA) | June 30, 2021 |
| Cefepime | 44567-131 | Injection, powder, for solution | Generic drugs (ANDA) | March 31, 2021 |
| Cefepime | 44567-130 | Injection, powder, for solution | Generic drugs (ANDA) | March 31, 2021 |
| Imipenem and Cilastatin | 44567-705 | Injection, powder, for solution | Generic drugs (ANDA) | March 9, 2021 |
| Midazolam in Sodium Chloride | 44567-611 | Injection, solution | New drug applications (NDA) | December 31, 2020 |
| Midazolam in Sodium Chloride | 44567-610 | Injection, solution | New drug applications (NDA) | December 31, 2020 |
| Levetiracetam | 44567-503 | Injection | New drug applications (NDA) | August 24, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.